Deciphering the cellular phase of AD using Single Cell Genomics

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The UK Dementia Research Institute (UK DRI) is an initiative funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. Funding details for UK DRI programmes will be added in 2019.

Dr. Carlo Sala Frigerio will move together with the director to the UCL hub and take the full responsibility of the single cell core of the institute. His aim is to contribute to the full understanding of the cellular phase of Alzheimer’s disease (AD) and to identify critical pathways and cell biological responses that might help to develop novel therapeutic approaches for AD. He has extensive experience in genetics, biochemistry, molecular and cellular biology and genomics, as demonstrated by his publications. Since two years he has set up the single cell biology core in the laboratory of Bart De Strooper and several publications are in preparation.
The move to UCL will allow to switch the focus of research towards human brain.

Organisations

Publications

10 25 50

 
Description The EU framework Programme for Research and Innovation (Horizon 2020)
Amount € 2,374,997 (EUR)
Funding ID DLV-834682 
Organisation European Commission H2020 
Sector Public
Country Belgium
Start 10/2019 
End 09/2024
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation 20Med Therapeutics
Country Netherlands 
Sector Private 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation European Research and Project Office GmbH
Country Germany 
Sector Private 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation Flemish Institute for Biotechnology
Country Belgium 
Sector Academic/University 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation Giovanni Lorenzini Italian Biochemical Institute
Country Italy 
Sector Private 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation Malvern Instruments
Country United Kingdom 
Sector Private 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation SINTEF
Country Norway 
Sector Multiple 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation University Medical Center Utrecht (UMC)
Country Netherlands 
Sector Academic/University 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description B-SMART Horizon 2020, B-SMART - Brain-Specific, Modular and Active RNA Therapeutics (2017-2021) 
Organisation University of Santiago de Compostela
Country Spain 
Sector Academic/University 
PI Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Collaborator Contribution The goal is to develop RNA therapeutics for Alzheimer's Disease. Our objectives are three-fold: To identify appropriate RNA oligonucleotide-sequences and chemical modifications for experimental work within the consortium and establish SOPs, to order single batch synthesis of material sufficient for the consortium and organize distribution and appropriate storage, and to compile and discuss performance of the RNAs regarding on and off-target effects. All partners contribute to these aims by exchanging information , tools and work
Impact On going goal to develop RNA therapeutics for Alzheimer's Disease.
Start Year 2017
 
Description C-FoS consortium 
Organisation Biogen
Country United Kingdom 
Sector Private 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Broad Institute
Country United States 
Sector Charity/Non Profit 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Denali Therapeutics
Country United States 
Sector Private 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation F Prime Capital
Country United States 
Sector Private 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Flemish Institute for Biotechnology
Country Belgium 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Icahn School of Medicine at Mount Sinai
Country United States 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation Stanford University
Country United States 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation The Jackson Laboratory
Country United States 
Sector Charity/Non Profit 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation University of California, Irvine
Country United States 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation University of California, San Diego (UCSD)
Country United States 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description C-FoS consortium 
Organisation University of Gothenburg
Country Sweden 
Sector Academic/University 
PI Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease. Bart is co-leader in the PRS/iPSC working group and member of the workgroups on Tools, Animal Models, Human samples, Bioinformatic Analyses and Shared Data Platform.
Collaborator Contribution The mission of this consortium is to elucidate the fundamental science of Alzheimer's mechanisms as a solid foundation for future drug discovery and clinical trials. We will characterize the role of immune cells in Alzheimer's disease and apply this to the detection and treatment of disease.
Impact Ongoing
Start Year 2018
 
Description Collaboration between Eisai and UKDRI 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution I have set up this collaboration as director of the DRI. The partner provides postdoctoral fellowships to people in the institute and I have been part of the selection committee
Collaborator Contribution The partner provides postdoctoral fellowships to people in the institute
Impact EISAI Funded Fellowships for Postdocs have become available at UKDI
Start Year 2019
 
Description Collaboration with Julija Krupic 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution In a search of the best mouse model of Alzheimer's disease: linking behavioural phenotypes with physiological changes
Collaborator Contribution The award made by UK DRI Ltd will provide a grant of up to £300,00.00 for up 36 months starting 1 Nov 2018
Impact na
Start Year 2018
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Aarhus University
Country Denmark 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation AbbVie (UK)
Country United Kingdom 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Academy of Athens
Department Biomedical Research Foundation Academy of Athens
Country Greece 
Sector Charity/Non Profit 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation H. Lundbeck A/S
Country Denmark 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Johnson & Johnson
Department Janssen Pharmaceutica
Country Global 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Public 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)
Country France 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation SCIPROM
Country Switzerland 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation Servier Laboratories
Department International Research Institute Servier
Country France 
Sector Private 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation University Medical Center Göttingen
Country Germany 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation University of Bordeaux
Country France 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description EU Innovative Medicines Initiative 2 Joint Undertaking (IMI2) H2020-IMI2: Inhibiting Misfolded Protein Propagation in Neurodegenerative Disease (2017-2021) 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Our role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Collaborator Contribution The overarching goal of the IMPRiND (Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases) consortium is to block misfolded pathogenic protein aggregation and propagation in neurodegenerative diseases. Oor role is to establish a chimeric mouse model to study TAU aggregation, propagation and role of TAU in neuronal cell death. Also, we will prioritize the animal models for the validation of genome-wide TAU aggregation screen hits. These hits will be provided by the other partners from the consortium.
Impact Ongoing
Start Year 2017
 
Description KU Leuven/UK DRI 
Organisation University of Leuven
Country Belgium 
Sector Academic/University 
PI Contribution Partnership between KU Leuven and UK DRI UCL allowing Prof. De Strooper to continue research efforts in Leuven
Collaborator Contribution KU Leuven provide research facilities
Impact NA
Start Year 2017
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Aarhus University
Country Denmark 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Academy of Athens
Department Biomedical Research Foundation Academy of Athens
Country Greece 
Sector Charity/Non Profit 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Austrian Academy of Sciences
Department Institute of Molecular Biotechnology
Country Austria 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Babraham Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Centre for Genomic Regulation (CRG)
Country Spain 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Curie Institute Paris (Institut Curie)
Country France 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation European Molecular Biology Laboratory
Country Germany 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation German Cancer Research Center
Country Germany 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Helmholtz Association of German Research Centres
Department The Max Delbrück Center for Molecular Medicine (MDC)
Country Germany 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Helmholtz Zentrum München
Country Germany 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Iuliu Hatieganu University of Medicine and Pharmacy
Country Romania 
Sector Hospitals 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation University of Leuven
Department VIB Switch Laboratory
Country Belgium 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation University of Technology of Compiègne
Department French National Centre for Scientific Research Lab (CNRS Lab)
Country France 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description LifeTime - FET Flagship: The LifeTime Initiative - Revolutionising healthcare by tracking, understanding, and treating human cells during disease. 
Organisation Weizmann Institute of Science
Country Israel 
Sector Academic/University 
PI Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Collaborator Contribution LifeTime is a coordination and support Action (CSA) from Horizon 2020. LifeTime wants to expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyze and predict cellular mechanisms and functions.
Impact UK DRI became thanks to my efforts an associated partner I led the bid for the neurodegenerative and brain disease aspect
Start Year 2019
 
Description Amyloid Transmissibility workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Experts in the area came together to discuss the latest science regarding the Amyloid Transmissibility and research that needs to take place in this area.
Year(s) Of Engagement Activity 2019
 
Description Announced of receiving ERC Advanced grant in Science Business 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Article published entitled: Seven ERC Advanced Grants for KU Leuven researchers.
Year(s) Of Engagement Activity 2019
URL https://sciencebusiness.net/network-news/seven-erc-advanced-grants-ku-leuven-researchers
 
Description Bart - Brexit interview feature 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Bart De Strooper: 'Bright young scientists won't come to join us in UK'
Year(s) Of Engagement Activity 2019
 
Description Comment in Anti Aging News 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bart comment on aducanumab news, UK DRI affiliation. Engaging the public with the current developments into new treatments.
Year(s) Of Engagement Activity 2019
URL https://www.worldhealth.net/news/first-drug-slow-down-alzheimers-disease/
 
Description Comment in Nation newspaper article -Daily Mail 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Commented in the article: Dementia is NOT inevitable: World Health Organization says exercising, eating healthy, quitting smoking and cutting back on alcohol can slash your risk of the disorder. To bring awareness to the public of health issues, health education.
Year(s) Of Engagement Activity 2019
URL https://www.dailymail.co.uk/health/article-7026963/Exercise-eat-healthy-diet-stop-smoking-slash-risk...
 
Description Comment in article - Bionews 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Bart commenced on article entitled "Scientists oppose proposal to close UK mouse-research centre"
Year(s) Of Engagement Activity 2019
URL https://www.bionews.org.uk/page_143623
 
Description Comment in article - Daily Mail 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bart comment on aducanumab news, UK DRI affiliation. Engaging the public in the outcomes of research into potential new treatments.
Year(s) Of Engagement Activity 2019
URL https://www.dailymail.co.uk/health/article-7600617/Company-says-seek-approval-Alzheimers-drug
 
Description Comment in article - The Times 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bart comment on aducanumab news, UK DRI affiliation. Engaging the public in developments in research into potential new treatments.
Year(s) Of Engagement Activity 2019
URL https://www.thetimes.co.uk/article/biogen-new-drug-offers-hope-for-alzheimer-s-sufferers-sh90z3q9h
 
Description Comment in article for national newspaper - The Sun 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Comment on aducanumab news, UK DRI affiliation. Engaging general public with current research into potential treatments.
Year(s) Of Engagement Activity 2019
URL https://www.thesun.co.uk/news/10192304/drug-slows-alzheimers-two-years/
 
Description Comment in article for the Science Magazine 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Bart comment on aducanumab news, UK DRI affiliation
Year(s) Of Engagement Activity 2019
URL https://www.sciencemag.org/news/2019/10/alzheimer-s-drug-resurrected-company-claims-clinical-benefit...
 
Description Comment in article on online forum EIN Newsdesk 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact interview before EAN talk - Early treatment is the key to beating Alzheimer's disease in later life. Engaging the public in the latest findings for dementia research
Year(s) Of Engagement Activity 2019
URL https://www.einnews.com/pr_news/489058861/early-treatment-is-the-key-to-beating-alzheimer-s-disease-...
 
Description Comment in online Science Website's article - IFLScience 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Comment in article "How To Reduce Your Risk Of Dementia, According To The WHO". To engage and educate the public in the latest WHO recommendations related to Dementia.
Year(s) Of Engagement Activity 2019
URL https://www.iflscience.com/health-and-medicine/how-to-reduce-your-risk-of-dementia-according-to-the-...
 
Description Comment in online article - BBC News 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bart comment on aducanumab news, UK DRI affiliation. Engaging the general public in potential treatments that are currently being research into
Year(s) Of Engagement Activity 2019
URL https://www.bbc.co.uk/news/health-50137041
 
Description Comment in online article at Maltwinds.com 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bart comment on aducanumab news, UK DRI affiliation. Engaging the general public in current research into potential new treatments.
Year(s) Of Engagement Activity 2019
URL https://www.newsweek.com/dementia-aging-study-brains-tests-1468657
 
Description Comments in article in the The Times newspaper 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Commented in press regarding Google ads on supplements. Article entitled "Google cashes in on dementia pills that give patients false hope". The purpose was to provide reliable information to the general public regarding the use and effectiveness of such supplements so that the general population is more informed.
Year(s) Of Engagement Activity 2019
URL http://www.thetimes.co.uk/edition/news/google-cashes-in-on-dementia-pills-that-give-patients-false-h...
 
Description Interview with AlzForum 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Interview entitled: Amid Brexhaustion, U.K. DRI Marches On, Seeks Innovation Director. Bringing awareness to the professional community of the fact that an Innovation Director is sought.
Year(s) Of Engagement Activity 2019
URL https://www.alzforum.org/news/research-news/amid-brexhaustion-uk-dri-marches-seeks-innovation-direct...
 
Description Presentation to scientists on Brain Prize 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact The 2018 Brain Prize was awarded to John Hardy (London), Bart De Strooper (London and Leuven), Michel Goedert (Cambridge) andChristian Haass (Munich) for their groundbreaking research on the genetic and molecular basis of Alzheimer's disease.
Year(s) Of Engagement Activity 2017
 
Description Press interview for article in Daily Mail entitled: How the war on dementia is being BLOCKED by dozens of unsuccessful drug trials, tight budgets and patients being too sick to test medications on 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Interview with journalist from the Daily Mail and quoted in article entitled: "How the war on dementia is being BLOCKED by dozens of unsuccessful drug trials, tight budgets and patients being too sick to test medications on", which was published on the 3rd of January 2020.
Year(s) Of Engagement Activity 2020
 
Description Royal Society, Brain Prize Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The 2018 Brain Prize was awarded to John Hardy (London), Bart De Strooper (London and Leuven), Michel Goedert (Cambridge) andChristian Haass (Munich) for their groundbreaking research on the genetic and molecular basis of Alzheimer's disease.
Year(s) Of Engagement Activity 2018
 
Description The Frontier's of Parkinson Disease Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The event was designed for UK multidisciplinary PD community to come together to share ideas and perspectives. Lots of positive feedback from participants.
Year(s) Of Engagement Activity 2019
 
Description UK Dementia Ecosystem workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The event was a forum to provide opportunities for collaboration and guests included academics, Industry partners, professional practitioners and funders.
Year(s) Of Engagement Activity 2019
 
Description UKDRI/ICM/Paris/DZBE/VIB collaboration 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Expert working group set up and due to meet in early 2020.
Year(s) Of Engagement Activity 2019
 
Description We could find a cure for dementia within the decade, claims expert 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact We could find a cure for dementia within the decade, claims expert
Year(s) Of Engagement Activity 2019